ArticleCancer prevention research (Philadelphia, Pa.)2018
AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health.
Article in Cancer prevention research (Philadelphia, Pa.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 47 citations in OpenAlex.
- Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success.ESMO open · 2026Review
- Article
- Mutation detection in women diagnosed with endometrial cancer: a next-generation sequencing analysis.Molecular & cellular oncology · 2026Article
- A framework and process for community-engaged, mixed-methods cancer needs assessments.Cancer causes & control : CCC · 2024Article
- Adult obesity treatment and prevention: A trans-agency commentary on the research landscape, gaps, and future opportunities.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2024Review
- An Integrated Cancer Prevention Strategy: the Viewpoint of the Leon Berard Comprehensive Cancer Center Lyon, France.Cancer prevention research (Philadelphia, Pa.) · 2024Article
- A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer.Journal of cancer immunology · 2024Article
- Endometriosis and epithelial ovarian cancer: a two-sample Mendelian randomization analysis.Scientific reports · 2023Article
- Review
- Emerging Trends in Cancer Prevention Agent Development.Journal of cancer prevention · 2023Article
- Natural Products in Precision Oncology: Plant-Based Small Molecule Inhibitors of Protein Kinases for Cancer Chemoprevention.Nutrients · 2023Review
- A qualitative exploration of facilitators and barriers of adherence to time-restricted eating.Appetite · 2022Article
- Hepatocellular Carcinoma Chemoprevention with Generic Agents.Seminars in liver disease · 2022Review
- Precision intervention for prostate cancer: Re-evaluating who is at risk.Cancer letters · 2022Review
- Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Sensei: how many samples to tell a change in cell type abundance?BMC bioinformatics · 2022Article
- A comprehensive role evaluation and mechanism exploration of POGLUT2 in pan-cancer.Frontiers in oncology · 2022Article
- Article
- Evaluating DNA Methylation in Random Fine Needle Aspirates from the Breast to Inform Cancer Risk.The breast journal · 2022Article
- Nipping Diseases in the Bud? Ethical and Social Considerations of the Concept of 'Disease Interception'.Public health ethics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Funding
Abstract
The recent pace, extent, and impact of paradigm-changing cancer prevention science has been remarkable. The American Association for Cancer Research (AACR) convened a 3-day summit, aligned with five research priorities: (i) Precancer Atlas (PCA). (ii) Cancer interception. (iii) Obesity-cancer linkage, a global epidemic of chronic low-grade inflammation. (iv) Implementation science. (v) Cancer disparities. Aligned with these priorities, AACR co-led the Lancet Commission to formally endorse and accelerate the NCI Cancer Moonshot program, facilitating new global collaborative efforts in cancer control. The expanding scope of creative impact is perhaps most startling-from NCI-funded built environments to AACR Team Science Awarded studies of Asian cancer genomes informing global primary prevention policies; cell-free epigenetic marks identifying incipient neoplastic site; practice-changing genomic subclasses in myeloproliferative neoplasia (including germline variant tightly linked to JAK2 V617F haplotype); universal germline genetic testing for pancreatic cancer; and repurposing drugs targeting immune- and stem-cell signals (e.g., IL-1β, PD-1, RANK-L) to cancer interception. Microbiota-driven IL-17 can induce stemness and transformation in pancreatic precursors (identifying another repurposing opportunity). Notable progress also includes hosting an obesity special conference (connecting epidemiologic and molecular perspectives to inform cancer research and prevention strategies), co-leading concerted national implementation efforts in HPV vaccination, and charting the future elimination of cancer disparities by integrating new science tools, discoveries and perspectives into community-engaged research, including targeted counter attacks on e-cigarette ad exploitation of children, Hispanics and Blacks. Following this summit, two unprecedented funding initiatives were catalyzed to drive cancer prevention research: the NCI Cancer Moonshot (e.g., PCA and disparities); and the AACR-Stand Up To Cancer bold "Cancer Interception" initiative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.